Natriuretic Peptides: A Cardiologist’s View
Natriuretic peptides are secreted from the heart as counter regulatory hormones in response to increased intraventricular and atrial pressure and stretch. Assays to measure natriuretic peptide concentrations have been clinically available for more than a decade primarily for the indication of diagnosing acute heart failure. To date, no other clinically available blood based biomarker has approached the diagnostic accuracy of the natriuretic peptide tests.
However, these recent guidelines expand natriuretic peptide testing beyond a diagnostic role, and also identify using their measurement for prognosis in established heart failure patients.
Determining the optimal timing of when to measure natriuretic peptides, particularly for admitted patients with AHF is challenging as levels may fluctuate dramatically over the course of treatment.
This webinar will present data supporting the use of the change in concentration or a pre-discharge value for optimal prognostication and explore alternative pathophysiologies and associated co-morbidities that contributes to elevated natriuretic peptide concentrations and ultimately a poor prognosis other than increased intracardiac pressures. The session will also review this data as well introduce an ongoing large NIH sponsored multi-center study designed to definitively address the exciting topic of the use of natriuretic peptide assays to optimize ambulatory heart failure management to reduce AHF admissions and death.
Dr. Christopher deFilippi, MD
Associate Professor of Medicine
Division of Cardiology
University of Maryland School of Medicine